rare respiratory diseases

Savara Inc. (SVRA) Soars: Phase 3 Trial Success Fuels Hopes for aPAP Treatment

Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, presented groundbreaking data from its Phase 3...